Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer
Chinese Journal of Lung Cancer, 2023 As one of the most common malignant tumors, lung cancer poses a serious threat to human life and health. The platinum-based drug cisplatin (DDP) is used as the first-line treatment for lung cancer.
Jinzhe SUN, Jun CHEN
doaj +1 more source
Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis [PDF]
, 2016 Human papillomavirus induced (HPV+) cancer incidence is rapidly rising, comprising 60–80% of oropharyngeal squamous cell carcinomas (OPSCCs); while rare, recurrent/metastatic disease accounts for nearly all related deaths.
Coppock, Joseph D +8 more
core +2 more sources
Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance [PDF]
ChemMedChem, 2014 AbstractCyclooxygenase (COX) is an enzyme involved in tumorigenesis and is associated with tumor cell resistance against platinum‐based antitumor drugs. Cisplatin analogues were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously observed in combination treatments.
Wilma, Neumann +7 more
openaire +2 more sources
The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
PLoS ONE, 2013 Resistance to cisplatin-based therapy is a major cause of treatment failure in human ovarian cancer. A better understanding of the mechanisms of cisplatin resistance will offer new insights for novel therapeutic strategies for this deadly disease.
Akechai Im-aram +6 more
doaj +1 more source
Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]
PLoS ONE, 2014 Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet +5 more
doaj +1 more source
European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. [PDF]
, 2019 Background: Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of patients but the underlying molecular mechanism(s) are unclear and there ...
Abedi, Sina +13 more
core +1 more source
Acta Biochimica et Biophysica Sinica, 2023 Cisplatin resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). p32 and OPA1 are the key regulators of mitochondrial morphology and function. This study aims to investigate the role
Yu Chun-Xia +8 more
doaj +1 more source
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]
, 2016 BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA +17 more
core +3 more sources
ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
Journal of Experimental & Clinical Cancer Research, 2018 Background ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the
Linlin Zhu +6 more
doaj +1 more source
Mechanisms of cross resistance between cisplatin and bleomycin in saccharomyces cerevisiae [PDF]
, 2019 Tumor cells can simultaneously acquire resistance against a diverse group of drugs. This phenomenon is called pleotropic resistance or multidrug resistance.
Burgos-Molina, Antonio Manuel +2 more
core